Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD).

Our study supports the clinical translation of such antibody-mediated inhibition of myostatin as a treatment of OPMD. This strategy has implications to be used as adjuvant therapies with gene therapy based approaches, or to stabilize the muscle prior to myoblast transplantation.